Abstract:Dengue virus (DENV) is a major mosquito-borne human pathogen in tropical countries; however, there are currently no targeted antiviral treatments for DENV infection. Compounds 27 and 29 have been reported to be allosteric inhibitors of DENV RdRp with potent inhibitory effects. In this study, the structures of compounds 27 and 29 were optimized using computer-aided drug design (CADD) approaches. Nine novel compounds were synthesized based on rational considerations, including molecular docking scores, free energy of binding to receptor proteins, predicted Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) parameters, structural diversity, and feasibility of synthesis. Subsequently, the anti-DENV activity was assessed. In the cytopathic effect (CPE) assay conducted on BHK-21 cells using the DENV2 NGC strain, both SW-b and SW-d demonstrated comparable or superior activity against DENV2, with IC50 values of 3.58 ± 0.29 μM and 23.94 ± 1.00 μM, respectively, compared to that of compound 27 (IC50 = 19.67 ± 1.12 μM). Importantly, both SW-b and SW-d exhibited low cytotoxicity, with CC50 values of 24.65 μmol and 133.70 μmol, respectively, resulting in selectivity indices of 6.89 and 5.58, respectively. Furthermore, when compared to the positive control compound 3′-dATP (IC50 = 30.09 ± 8.26 μM), SW-b and SW-d displayed superior inhibitory activity in an enzyme inhibitory assay, with IC50 values of 11.54 ± 1.30 μM and 13.54 ± 0.32 μM, respectively. Molecular dynamics (MD) simulations elucidated the mode of action of SW-b and SW-d, highlighting their ability to enhance π–π packing interactions between benzene rings and residue W795 in the S1 fragment, compared to compounds 27 and 29. Although the transacylsulphonamide fragment reduced the interaction between T794 and NH, it augmented the interaction between R729 and T794. In summary, our study underscores the potential of SW-b and SW-d as allosteric inhibitors targeting the DENV NS5 RdRp domain. However, further in vivo studies are warranted to assess their pharmacology and toxicity profiles.

Discovery and SAR Studies of Methionine–proline Anilides As Dengue Virus NS2B-NS3 Protease Inhibitors

Identification of Fused Bicyclic Derivatives of Pyrrolidine and Imidazolidinone As Dengue Virus-2 NS2B-NS3 Protease Inhibitors

Identification of Novel Thiadiazoloacrylamide Analogues As Inhibitors of Dengue-2 Virus NS2B/NS3 Protease.

Design, synthesis and biological activity evaluation of novel allosteric inhibitors of the DENV NS2B–NS3 protease

Peptide Inhibitors of Dengue Virus Ns3 Protease. Part 2: Sar Study of Tetrapeptide Aldehyde Inhibitors

Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease.

Discovery Of Novel Small Molecule Inhibitors Of Dengue Viral Ns2b-Ns3 Protease Using Virtual Screening And Scaffold Hopping

Discovery of highly potent DENV NS2B-NS3 covalent inhibitors containing a phenoxymethylphenyl residue

Discovery of Potent Dengue Virus NS2B-NS3 Protease Inhibitors Among Glycyrrhizic Acid Conjugates with Amino Acids and Dipeptides Esters

Tripeptide Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease.

Design, Synthesis, Evaluation and Molecular Dynamics Simulation of Dengue Virus NS5-RdRp Inhibitors

Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors.

Critical Effect of Peptide Cyclization on the Potency of Peptide Inhibitors Against Dengue Virus NS2B-NS3 Protease.

Docking and Qm/Mm Studies of Ns2b-Ns3pro Inhibitors: A Molecular Target Against the Dengue Virus

Antiviral Drug Discovery with an Optimized Biochemical Dengue Protease Assay: Improved Predictive Power for Antiviral Efficacy

3D-QSAR Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulation Toward Identifying Lead Compounds for NS2B-NS3 Protease Inhibitors.

Computational design and in vitro assay of lantadene-based novel inhibitors of NS3 protease of dengue virus

Investigating Lycotoxin-An1a (An1a), a defense antiviral peptide from Alopecosa nagpag venom as prospective anti-dengue agent against DENV-2 NS2B-NS3 protease

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Design, Synthesis, and Biological Evaluation of Substituted 4,6-Dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3 '-Indoline]-2 ',5(3H)-Dione Analogues As Potent NS4B Inhibitors for the Treatment of Dengue Virus Infection

Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors